

TEPEZZA ACCESS & SUPPORT: **ONE-STOP RESOURCE**

Navigating access and support for your patients
with Thyroid Eye Disease.

over **25k**

patients* treated across
3000+ sites of care^{1,2}

6 years

of **real-world experience**
and counting³

4 **global
clinical
trials**

and ongoing
data exploration⁴⁻⁷

*Based on 25,062 individual patients enrolled in Amgen By Your Side who received at least 1 dose of TEPEZZA from 02/05/2020 – 11/14/2025. TED diagnosis is assumed based on initiation of TEPEZZA. TED, Thyroid Eye Disease.


INDICATION AND IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Please see additional Important Safety Information throughout and on page 19 and [Full Prescribing Information](#).



Share this brochure with your patient. It explains what a **Patient Access Liaison (PAL)** is and how they can support them throughout their treatment journey.



BROAD ACCESS AND SUPPORT YOU CAN COUNT ON



Access guidance for when you're ready to prescribe.

This guide provides the essential steps and resources to help your office navigate coverage, reimbursement, and support for your TEPEZZA patients.

Inside you'll find:

- 1 Steps to initiate enrollment in Amgen By Your Side
- 2 Tools for prior authorization and claim submission
- 3 Support programs for patients and offices

TEPEZZA is indicated for the treatment of TED regardless of disease activity or duration.⁸ Amgen is committed to partnering with you and your patients every step of the way.

TEPEZZA is now more accessible than ever with 98% coverage across commercial and government insurance types^{9,*}

92%

of insured patients
have no CAS threshold
requirement¹⁰

91%

of covered lives do not
require a mandatory
steroid step¹⁰

78%

of patients receive
approval after their
first PA¹¹

*Based on commercial and government plans analyzed. Individual patient access varies.
CAS, Clinical Activity Score; PA, Prior Authorization.

IMPORTANT SAFETY INFORMATION

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Please see additional Important Safety Information throughout and on page 19.

TEPEZZA
teprotumumab-trbw



Patients who are diagnosed with Thyroid Eye Disease are confronting a variety of issues. I want them to understand that I will be a point person for them. I look at my role as being able to help them as they navigate the insurance and treatment processes."

— Carol E, PAL



AMGEN BY YOUR SIDE: SUPPORT FOR PATIENTS PRESCRIBED TEPEZZA, THROUGHOUT THEIR JOURNEY



Dedicated Patient Access Liaisons (PAL): Every patient is paired with a PAL who provides one-on-one support—from education on benefits investigation to treatment coordination.



Infusion and access support: PALs help educate patients on site-of-care options, insurance, and financial support to help patients access their treatment as prescribed.



Treatment logistics support: Patients receive ongoing education and appointment reminders to help them stay on track with treatment goals.



TED Team Peer-to-Peer Program: Connects prescribed patients with peers who've completed TEPEZZA treatment to share real-world experience and offer encouragement.



Amgen Commercial Co-Pay Program: Eligible patients with commercial insurance may pay as little as **\$0 out-of-pocket*** for the cost of the medication and the infusion administration through the Amgen Commercial Co-Pay Program.

*Eligibility criteria and program maximums apply. See <https://www.tepezzahcp.com/amgen-by-your-side> for full terms and conditions. Patients who are residents of Massachusetts or Rhode Island are not eligible for administration support.

IMPORTANT SAFETY INFORMATION

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary.

Please see additional Important Safety Information throughout and on page 19.



— Kim E, Real TEPEZZA Patient

Kim E was compensated for her time.

AFTER YOU DECIDE TEPEZZA IS RIGHT FOR YOUR PATIENT, SUBMIT THE PATIENT ENROLLMENT FORM (PEF)

The PEF initiates enrollment in Amgen By Your Side on your patients' behalf. Here are a few things to remember:

- The PEF must be dated and signed by both the **physician** and the **patient**
- Patient needs to check the "**I consent**" box in order to be enrolled into Amgen By Your Side
- Include a copy of the patient's insurance card (front and back)
 - Consider adding the patient demographic sheet
- If applicable, fill out the co-managing/referring physician section of the PEF so that we can ensure they are part of the patient's care team



Submit the PEF

Scan the QR code or visit TEPEZZApef.com to access the PEF and submit one of two ways:

Online: Fill out the form, sign, and submit through DocuSign®

or

Offline: Fill out the form, then download, sign, and fax the form to 1-833-469-8333 OR email it to TEPEZZAABYS@amgen.com

CONNECTING PATIENTS WITH THEIR AMGEN BY YOUR SIDE PATIENT ACCESS LIAISON

The PAL is a dedicated support partner who helps investigate, explain, and educate on the steps in your patient's treatment experience. They are your patient's point of contact and champion while your patient is accomplishing their treatment goals.

- ✓ Make sure the patient is aware their PAL will be calling them in the next few days to provide information on next steps, the infusion process, and getting started on TEPEZZA
- ✓ Provide the patient with the PAL's contact information to ensure they have it readily available
 - It is important that the patient answers the PAL's call, which will appear on their phone as "Amgen By Your Side"
 - Encourage patients to save this contact to avoid the call being flagged as spam



Connect patients with their PAL. Remember to provide a PAL brochure (located on the inside front cover) to your patients.

“ *They assigned me a PAL after I was approved for treatment. They helped guide me through the process as far as what to expect, the process that I was going to go through, and just to provide general support for me.”*

— Randi C, Real TEPEZZA Patient

Randi C was compensated for her time.



EDUCATE PATIENTS ON WHAT TO EXPECT

When you identify an appropriate patient for TEPEZZA, provide educational materials to help them understand the treatment process and what to expect.

Share these resources whether you've already submitted a PEF or the patient is still considering therapy.



TEPEZZA Education Brochure A comprehensive resource for patients that was provided to your office. You can access the brochure online using the QR code found on page 17 in the Resources & Contacts section.



Getting Started Video

A video to help your patients understand how to get started on TEPEZZA. Scan the QR code or visit TEPEZZAstart.com



TEPEZZA Pre-Infusion Reminder List

A list that helps your patients prepare for TEPEZZA infusions.



TEPEZZA Post-Infusion Reminder List

A list that helps your patients stay on track after each TEPEZZA infusion.

Additional patient resources are available at TEPEZZA.com

Please see Important Safety Information throughout and on page 19.



PRIOR AUTHORIZATION TIPS

- After identifying a patient for TEPEZZA, begin collecting the clinical details most frequently requested during prior authorization
- Work with their PAL to review and understand your patient's payer medical policy
 - Common criteria may include prior treatments for TED; thyroid labs (T3, T4, FT3, FT4, TSH, TSI, TBII); or documentation of common signs and symptoms that suggest TED
- Include relevant clinical history, such as steroid use or contraindication, onset of symptoms, and current manifestations
- Document CAS and severity to describe patient's condition
- Confirm prescriber specialty (ophthalmologist, endocrinologist, neuro-ophthalmologist) as required by payer policy

Please note: Clinical Documentation should NOT be submitted with the PEF



- Clinical Documentation Tearpad
Scan the QR code or visit TEPEZZAcas.com



- Letter of Medical Necessity
Scan the QR code or visit TEPEZZALOMN.com



Payer Appeal Templates Available for PA

Whether your patient has commercial, government, or no insurance, the Amgen By Your Side team is committed to partnering with your patient to educate them on insurance coverage criteria and help them understand the financial support options that are available.

Scan the QR code to access TEPEZZAappeal.com

ACCESS RESOURCES AVAILABLE FOR YOUR PRACTICE

Financial Support

Based on the patient's insurance coverage and eligibility, the PAL will help identify appropriate resources to help reduce out-of-pocket costs so the patient can access their treatment as prescribed. For those that are eligible, the PAL can guide patients through the Amgen Commercial Co-Pay Program process.



Amgen Commercial Co-Pay Program

Eligible patients with commercial insurance may pay as little as \$0 out-of-pocket for the cost of the medication and the infusion administration through the Amgen Commercial Co-Pay Program.*

*Eligibility criteria and program maximums apply. See <https://www.tepezzahcp.com/amgen-by-your-side> for full terms and conditions. Patients who are residents of Massachusetts or Rhode Island are not eligible for administration support.



For access information specific to your region, connect with your SAM using the business card on the back of this piece.

SAM, Specialty Account Manager.

IMPORTANT SAFETY INFORMATION

Hyperglycemia (cont'd): Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Please see additional Important Safety Information throughout and on page 19.

TEPEZZA
teprotumumab-trbw



*Through the course of treatment,
my PAL became a trusted partner,
playing a critical role to help move
me through the process."*

— Annie L, Real TEPEZZA Patient
Annie L was compensated for her time.

YOU CAN PRESCRIBE TEPEZZA WITHOUT MANAGING INFUSIONS DIRECTLY

Flexible infusion options to fit your practice

Established Infusion Process:



- 8 IV infusions every 3 weeks (~5 months total)
- Infusion duration—plan for approximately 90 minutes per session to accommodate scheduling and patient response

Over 3000 Site of Care Options:



- Infusion centers
- Other clinics or physician offices
- Hospitals
- Home infusion (where available)



Use the Amgen Rare Disease Site Locator Tool to identify infusion locations near your patients

Scan the QR code to access AmgenRareDiseaseLocator.com

Your Area Lead (Site of Care) can help you throughout the infusion process

The Area Lead (Site of Care) is your main Amgen point of contact who establishes business-to-business relationships with sites of care and expands the network of infusion center options. The team educates on coding, billing, payer access, and provides product in-servicing to help patients access their treatment as prescribed.

IV, intravenous.

Please see Important Safety Information throughout and on page 19.

TEPEZZA
teprotumumab-trbw

ESSENTIAL CODES AT YOUR FINGERTIPS

Updated ICD-10-CM codes now include TED-specific options

Coding element	Information for TEPEZZA	Description
10-digit-NDC	75987-130-15	500 mg teprotumumab-trbw in a single-dose vial (lyophilized powder for injection for intravenous infusion)
11-digit-NDC	75987-0130-15	500 mg teprotumumab-trbw in a single-dose vial (lyophilized powder for injection for intravenous infusion)
ICD-10-CM Diagnosis Code	H05.831	Thyroid orbitopathy, right orbit
	H05.832	Thyroid orbitopathy, left orbit
	H05.833	Thyroid orbitopathy, bilateral
	H05.839	Thyroid orbitopathy, unspecified orbit
HCPCS drug code	J3241	Injection, teprotumumab-trbw, 10 mg

Payer requirements regarding the use of the 10- or 11-digit NDC may vary. Electronic data exchange generally requires use of the 11-digit NDC as listed above. Some payers may require both NDC numbers on the claim. Check payer requirements for appropriate reporting of the NDC.

HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

When billing for TEPEZZA using J3241, 1 unit represents 10 mg of TEPEZZA. TEPEZZA should be billed based on units, not the number of milligrams.

IMPORTANT SAFETY INFORMATION

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

Please see additional Important Safety Information throughout and on page 19.

Coding element	Information for TEPEZZA	Description
HCPCS Drug Administration Codes for Specialty Pharmacy Providers (SPP)	S9329	Home infusion therapy, chemotherapy infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with S9330 or S9331)
	S9379	Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
	S9810	Home therapy; professional pharmacy services for provision of infusion, specialty drug administration, and/or disease state management, not otherwise classified, per hour (do not use this code with any per diem code)
CPT® Drug Administration Codes for Physician Offices and Hospital Outpatient Departments	96413	Highly complex drugs, including biologic agents or chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
	96415	Highly complex drugs, including biologic agents or chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary procedure)
	96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
	96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure)
CPT® Drug Administration Codes for SPP	99601	Home infusion/specialty drug administration, per visit (up to 2 hours)
Modifier*	JW	Drug amount discarded/not administered to any patient
	JZ	Zero drug amount discarded/not administered to any patient

Payer coding requirements may vary. Consult individual payer policies for specific coding and documentation requirements.

CPT Copyright 2025 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

*As of July 1, 2023, CMS requires the "JZ" modifier to be reported on claims. Claims processing edits were implemented by the Medicare Administrative Contract in October 2023.

CPT, Common Procedural Terminology.

Please see additional Important Safety Information throughout and on page 19.

TEPEZZA
teprotumumab-trbw

“

My PAL was amazing. She would join calls with me and help me advocate. You have different people telling you different information, and when it would get complex my PAL would step in.”

— Lily Z, Real TEPEZZA Patient

Lily Z was compensated for her time.

RESOURCES & CONTACTS

Quick links for you



Patient Enrollment Form (PEF) Scan the QR code to access TEPEZZApef.com and initiate Amgen By Your Side Support.



Clinical Documentation Guide Scan the QR code to access TEPEZZAcas.com for step-by-step requirements for prior authorization (labs, symptoms, criteria).



Billing & Coding Guide Scan the QR code to access AmgenByYourSide.com/TEPBilling for ICD-10, J3241, NDC guidance for accurate claims submission.



Infusion Administration Video Scan the QR code to access a short video for infusion nurses on infusion prep and administration.

Quick links for your patient



Getting Started Video Scan the QR code to access TEPEZZAstart.com and educate patients on what to expect with TEPEZZA therapy.



Infusion Expectations Video
Walk-through of the infusion process and site-of-care options.



Patient Education Brochure
Easy-to-read guide for patients beginning TEPEZZA.

Who to contact



- **SAM:** Your SAM's contact details are on the back cover
 - Infusion site coordination and in-servicing
- **PAL:** Your patient's PAL's contact details are on the back cover
 - Patient education and treatment support
- **Amgen By Your Side:** 1-833-5-TEPEZZA (1-833-583-7399)



Please see Important Safety Information on page 19.



INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 5\%$ and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, ear discomfort, weight decreased, nail disorders, and menstrual disorders.

Please visit TEPEZZAhcp.com for more information.

References: 1. Data on File. Amgen, November 2025. 2. Data on File. Amgen, October 2025. 3. FDA. FDA approves first treatment for thyroid eye disease. January 2020 News Release. 4. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. *N Engl J Med*. 2020;382(4):341-352. 5. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. *N Engl J Med*. 2017;376(18):1748-176. 6. Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment. *Ophthalmology*. 2022;129:438-449. 7. Douglas RS, Couch S, Wester ST, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. *J Clin Endocrinol Metab*. 2024;109(1):25-35. 8. TEPEZZA (teprotumumab-trbw) [prescribing information] Amgen. 9. Data on File. Amgen, September 2025. 10. Data on File. Amgen, September 2025. 11. Data on File. Amgen, August 2025.

CONFIDENCE IN ACCESS. SUPPORT EVERY STEP.



TEPEZZA is now more accessible than ever with 98%* coverage across commercial and government insurance types⁹

*Based on commercial plans analyzed, individual patient access varies.



Amgen Commercial Co-Pay Program

*Eligible patients with commercial insurance may pay as little as **\$0 out-of-pocket[†]** for the cost of the medication and the infusion administration through the Amgen Commercial Co-Pay Program.*

[†]Eligibility criteria and program maximums apply. See <https://www.tepezzahcp.com/amgen-by-your-side> for full terms and conditions. Patients who are residents of Massachusetts or Rhode Island are not eligible for administration support.

Once you prescribe TEPEZZA, Amgen By Your Side provides:



- Dedicated PAL for one-on-one support
- Infusion and access coordination
- Treatment logistics and reminders
- TED Team Peer-to-Peer program for patient encouragement



Download the Patient Enrollment Form

Scan the QR code or visit [TEPEZZApef.com](https://www.tepezzahcp.com)



© 2026 Amgen Inc. All rights reserved. USA-632-81423 04/26

